Estradiol + progesterone
A fixed oral combination for moderate-to-severe menopausal vasomotor symptoms in women with a uterus.
FDA-approved product context
A fixed oral combination for moderate-to-severe menopausal vasomotor symptoms in women with a uterus.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The February 2026 label describes an estrogen-plus-progesterone capsule combination with a defined menopausal vasomotor-symptom indication. It records an initial U.S. approval and product-specific labeling changes.
Warnings and contraindications remain despite changes to the boxed warning. Thromboembolic disease, malignancy, liver disease and individual risk factors still require assessment. This is not approval of every custom hormone mixture.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Original source: Estradiol + progesterone ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.